NASDAQ · Financial Statements
Entero Therapeutics, Inc. (ENTO) Financial Statements
$2.85
NASDAQ: ENTO
Market Cap $13.58M
Overview Financials Dividend Entero Therapeutics, Inc. most recently reported annual revenue of $0, net profit of $-7.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-59.0M $-13.0M $-16.0M $0 $-7.0M Net Profit $-59.0M $-15.0M $-16.0M $-18.0M $-7.0M EPS $-27544.98 $-407.37 $-46.96 $-5.26 $-4.16 Op Margin — — — — -19540.0%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $12.0M $5.0M $7.0M $85.0M $49.0M Total Liabilities $20.0M $3.0M $3.0M $28.0M $20.0M Cash $8.0M $1.0M $4.0M $0 $1.0M Borrowings $1.0M $1.0M $1.0M $0 $2.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-32.0M $-22.0M $-12.0M $-9.0M $-6.0M Investing Cash Flow $-21.0M $0 $-1.0M $0 $0 Financing Cash Flow $5.0M $-7.0M $0 $0 $6.0M Net Cash Flow $2.0M $-7.0M $2.0M $-4.0M $1.0M Free Cash Flow $-43.0M $-22.0M $-13.0M $-9.0M $-6.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.06 EV / EBITDA -1.82 FCF Yield -51.67% Quick Ratio 0.16 Interest Coverage -9.93 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock